GlassScriptPhysician profile
Jennifer Chang
NPI 1669888558
$1,740.89
in general payments reported to CMS, 2019-2025
24 companies · $785 in 2025
The $785 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $225 · 2023: $111 · 2024: $620 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.17 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $235.42 | 2022-2025 | Xtandi |
| Abbvie INC. | $186.73 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $143.26 | 2024-2025 | |
| Celgene Corporation | $142.52 | 2024-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $125.33 | 2024-2025 | Iclusig, Livtencity, Ninlaro |
| Janssen Biotech, INC. | $114.17 | 2025 | Rybrevant, Talvey, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $96.81 | 2022 | |
| Merck Sharp & Dohme LLC | $83.76 | 2024-2025 | Keytruda, Keytruda Qlex |
| Myriad Women'S Health, INC. | $82.76 | 2023 | Myrisk |
| Pfizer INC. | $61.58 | 2024 | |
| Stemline Therapeutics INC. | $60.45 | 2024-2025 | Elzonris |
| Daiichi Sankyo INC. | $57.91 | 2024-2025 | Vanflyta |
| Array Biopharma INC | $48.21 | 2025 | Braftovi |
| Regeneron Healthcare Solutions, INC. | $47.34 | 2023-2024 | Libtayo |
| Genzyme Corporation | $46.81 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $29.78 | 2025 | Voraxaze |
| Lilly USA, LLC | $28.64 | 2024 | Retevmo |
| Pharmacosmos Therapeutics INC. | $24.42 | 2024 | Cosela |
| Exelixis INC. | $23.08 | 2025 | Cabometyx |
| Sun Pharmaceutical Industries INC. | $22.49 | 2024 | |
| Servier Pharmaceuticals LLC | $21.80 | 2025 | |
| Kyowa Kirin, INC. | $19.59 | 2024 | Poteligeo |
| Sobi, INC | $19.17 | 2025 | |
| Eisai INC. | $18.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.